Catalyst Event
Merck and Co Inc (MRK) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/18/2026, 12:00:00 AM
Merck's Animal Health unit received FDA approval on March 18, 2026, for an expanded label for Bravecto Quantum, a once-yearly injectable parasiticide for dogs, to treat and control Asian longhorned and Gulf Coast ticks.
Korean Translation
머크의 동물 의약품 사업부가 2026년 3월 18일, 1년 1회 주사하는 반려견용 구충제 브라벡토 퀀텀(Bravecto Quantum)에 대해 아시아 긴뿔 진드기 및 걸프 코스트 진드기 치료 및 제어를 포함하도록 확대된 라벨을 FDA로부터 승인받음.
Related Recent Events
Ionis Pharmaceuticals Inc (IONS) · Other
FDA target action (PDUFA) date for olezarsen for the treatment of severe hypertriglyceridemia (sHTG) following acceptance of sNDA for Priority Review. This is a major potential approval for a broad patient population, scheduled.
6/30/2026, 12:00:00 AM
Biogen Inc (BIIB) · Earnings Release
Q1 2026 earnings release (Low impact estimated as routine earnings releases typically see at least 1% volatility) scheduled.
5/6/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Bristol-Myers Squibb is scheduled to announce its first-quarter 2026 financial results on April 30, 2026, scheduled.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled; a price impact of at least 1% is expected.
4/30/2026, 12:00:00 AM
Teva Pharmaceutical Industries Ltd (TEVA) · Earnings Release
Teva is scheduled to release its first quarter 2026 financial results and host a conference call on April 29, 2026; importance is estimated at Medium as earnings reports typically drive significant price volatility, expected.
4/29/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
First quarter 2026 earnings results are scheduled to be released on April 23, 2026. This is expected to have a low impact as a routine financial update, scheduled.
4/23/2026, 12:00:00 AM